Cencora (COR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Cencora (COR) is widely expected to report a year-over-year increase in earnings and revenue for the quarter ended June 2025, with consensus estimates at $3.78 EPS (+13.2%) on $80.33 billion in revenue (+8.2%), ahead of its August 6 release. A positive Zacks Earnings ESP of +1.49% combined with a Zacks Rank #2 strongly suggests the company is highly likely to exceed consensus EPS estimates, building on its track record of beating estimates in the past four consecutive quarters. While an earnings beat is probable, investors should consider other factors influencing stock performance.

Analysis

Cencora (COR) is positioned for a strong earnings report for the quarter ending June 2025, with consensus estimates pointing to significant year-over-year growth. Expectations are for a 13.2% increase in earnings to $3.78 per share and an 8.2% rise in revenues to $80.33 billion. The bullish outlook is reinforced by several key quantitative indicators. The consensus EPS estimate has been revised upward by 0.39% in the last 30 days, signaling growing analyst confidence. More significantly, the proprietary Zacks Earnings ESP (Expected Surprise Prediction) stands at a positive 1.49%. When combined with the stock's Zacks Rank #2 (Buy), this model suggests a high probability—historically near 70%—of Cencora exceeding the consensus EPS estimate. This potential for a positive surprise is further supported by the company's consistent performance, having beaten EPS estimates in each of the last four quarters, including a notable +8.33% surprise in the most recent reporting period. While an earnings beat is not the sole driver of stock performance, the confluence of positive estimate revisions, a strong quantitative surprise model, and a history of outperformance presents a compelling case for the upcoming release on August 6. The contrast with industry peer Organon (OGN), which is expected to report year-over-year declines in both revenue and earnings, further highlights Cencora's relative strength within the Medical Services sector.

Key Decisions for Investors

• Given the high probability of an earnings per share beat, supported by a positive +1.49% Earnings ESP and a Zacks Rank #2, investors may consider maintaining or increasing long exposure to Cencora ahead of its August 6 report.
• It is critical to monitor management's forward-looking guidance and commentary on business conditions during the earnings call, as this will be a key determinant of the stock's price movement beyond the initial reaction to headline results.
• Investors should note Cencora's projected growth, with EPS expected up 13.2% and revenue up 8.2%, which stands in stark contrast to the expected declines at industry peer Organon, highlighting COR's relative fundamental strength.